FATE

Fate Therapeutics Inc. (FATE) | Rumor.io

Fate Therapeutics

FATE

Attention (50-day avg)0%

Attention rank (50-day avg)#2,378

Bullish sentiment (50-day avg)80%

Price to earnings ratio-2.07

Market capitalization285.2M

Earnings per share-1.05

Dividend yield (TTM)—

Revenue (annual)6.6M

Net income (annual)-136.3M

Social

What share of all stock conversation is about FATE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Jul 1

$FATE has seen a 24% increase in the last 2 days.
The stock's recent performance has been a topic of excitement among investors, with some expecting it to reach $3.00 or even $5.
Short interest in $FATE has dropped significantly, contributing to the stock's positive momentum.

Generated by AI

Sentiment

Of the messages about FATE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	53.85% -31.87	75% -15.48	85.36% +6.34
Bearish	—	46.15% +31.87	25% +15.48	14.64% -6.34

Bullish· May 5

$FATE is expected to reach $3-5 in May due to its unstoppable momentum.
Fate Therapeutics' pipeline for disease SLE has a very big potential, with a high probability of FDA approval, potentially reaching $5 in Q2.
$FATE has a strong balance sheet and a good amount of cash, which could lead to a price move to $3.5-3.75 before returning to $2.3-2.5.

Bearish· Jan 9

$FATE has been downgraded by multiple analysts, including Cowen to "Market Perform" and Piper Sandler.
$FATE is not profitable, which makes it a stock not worth buying.
$FATE's recent price increase is likely a short-term anomaly, as indicated by the RSI indicator and the author's own experience with the stock.

Generated by AI

Topics

Of the messages about FATE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	14.29%	30.15%
Announcements	—	0%	57.14%	60.3%
Controversies	—	0%	28.57%	0.28%
Analysts	—	0%	0%	8.58%
Earnings	—	0%	0%	0.69%
Macro	—	0%	0%	0%

Analysts· Jan 6

Analysts have downgraded Fate Therapeutics' stock to "Hold" or "Underperform" due to concerns over its pipeline and Janssen deal termination.
The average price target for Fate Therapeutics has decreased to $22.40, down from $59.15, following analyst downgrades and target cuts.
Several analysts have lowered their price targets for Fate Therapeutics, with some targets decreasing by as much as $63, citing concerns over the company's pipeline and deal termination.

Announcements· Nov 18

Fate Therapeutics' FT522 showed efficacy in a Phase 2 B-cell lymphoma trial, with favorable safety profile, complete responses, and persistence of FT522 live cells.
The company presented 6-month follow-up data on the first patient treated in a Phase 1 autoimmunity study with FT819, an off-the-shelf, 1XX CAR T-cell product candidate, with fludarabine-free conditioning.
Fate Therapeutics highlighted its FT522 off-the-shelf, ADR-armed CAR NK cell product candidate at the 2024 ACR Convergence, showcasing its novel technology for effective treatment of patients without intense conditioning chemotherapy.

Generated by AI

Community

Of the messages about FATE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	82.76%	90.91%	65.43%
Newcomers	0%	17.24%	9.09%	34.57%

Regulars· May 4

STIFEL remains cautious on the potential of FT819 and FT576 to differentiate themselves from existing CAR-T therapies, citing a high clinical bar and competition from established treatments.
Cantor Fitzgerald has trimmed their target price for Fate Therapeutics to $5.00, citing concerns about the company's ability to meet the high expectations set by its clinical trials.
Fate Therapeutics has reported strong earnings results for Q1 2023, beating expectations by $0.36 EPS, but its shares have still declined by 9.3% due to concerns about the company's clinical trials and competitiveness.

Newcomers· Nov 18

The focus on Fate Therapeutics' FT819 product candidate is on its potential to provide a complete game-changer for off-the-shelf CAR T-cell therapy, with promising results in a Phase 1 Autoimmunity study for lupus nephritis.
The company's cash reserves and market capitalization are notable, with $330M in cash and a market cap of $300M, making it an attractive investment opportunity.
Fate Therapeutics' FT522 product candidate has demonstrated efficacy in a Phase 1 B-Cell Lymphoma trial, with promising initial data presented at the American College of Rheumatology Convergence.

Generated by AI

News

Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial

Fate Therapeutics (FATE) has been awarded a $15 million grant from the California Institute for Rege

6d agoYahoo Finance

Fate Therapeutics receives $15m CIRM grant for lupus trial

6d agoInvesting.com

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the potential to provide transformative benefits to patients and the healthcare system SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical c

6d agoYahoo Finance Singapore

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-1

15d agofinance.yahoo.com

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances

21d agoInvesting.com

Fate Therapeutics presents FT819 lupus trial data at conference

22d agoInvesting.com

Also Discussed

Investors talking about FATE also mention

#	Name	Attention
1	Century Therapeutics IncIPSC	0%+0
2	AFMD - Affimed N.V.	——
3	Beam Therapeutics IncBEAM	0.03%+0.03
4	Cellectis S.A. ADRCLLS	0%new
5	Palvella Therapeutics IncPIRS	0%0
6	Caribou Biosciences, Inc.CRBU	0%new
7	Arrowhead Pharmaceuticals, Inc.ARWR	0%0
8	Nkarta, Inc.NKTX	0%new
9	Editas Medicine, Inc.EDIT	0%0
10	MRTX - Mirati Therapeutics, Inc.	——

Fate Therapeutics Inc.

Healthcare
Biotechnology

Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing programmed cellular immunotherapies for cancer and immune-related diseases. The company uses its proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf cell therapy candidates, including natural killer (NK) cell and T-cell programs designed to address key limitations in traditional cell manufacturing. Its portfolio centers on immuno-oncology and immuno-regulatory applications, with product candidates aimed at treating solid tumors, blood cancers, and autoimmune disorders. Fate Therapeutics also applies its cell programming approach to engineer synthetic controls of cell function and produce renewable master cell lines for scalable development. Headquartered in San Diego, California, Fate Therapeutics plays a specialized role in the advanced cell therapy market, where it supports the transition from donor-derived treatments to more standardized, engineered therapeutic products.

Website

Location

12278 Scripps Summit Drive

San Diego, CA, 92131

United States

Social

What share of all stock conversation is about FATE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Jul 1

$FATE has seen a 24% increase in the last 2 days.
The stock's recent performance has been a topic of excitement among investors, with some expecting it to reach $3.00 or even $5.
Short interest in $FATE has dropped significantly, contributing to the stock's positive momentum.

Generated by AI

Sentiment

Of the messages about FATE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	53.85% -31.87	75% -15.48	85.36% +6.34
Bearish	—	46.15% +31.87	25% +15.48	14.64% -6.34

Bullish· May 5

$FATE is expected to reach $3-5 in May due to its unstoppable momentum.
Fate Therapeutics' pipeline for disease SLE has a very big potential, with a high probability of FDA approval, potentially reaching $5 in Q2.
$FATE has a strong balance sheet and a good amount of cash, which could lead to a price move to $3.5-3.75 before returning to $2.3-2.5.

Bearish· Jan 9

$FATE has been downgraded by multiple analysts, including Cowen to "Market Perform" and Piper Sandler.
$FATE is not profitable, which makes it a stock not worth buying.
$FATE's recent price increase is likely a short-term anomaly, as indicated by the RSI indicator and the author's own experience with the stock.

Generated by AI

Topics

Of the messages about FATE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	100%	14.29%	30.15%
Announcements	—	0%	57.14%	60.3%
Controversies	—	0%	28.57%	0.28%
Analysts	—	0%	0%	8.58%
Earnings	—	0%	0%	0.69%
Macro	—	0%	0%	0%

Analysts· Jan 6

Analysts have downgraded Fate Therapeutics' stock to "Hold" or "Underperform" due to concerns over its pipeline and Janssen deal termination.
The average price target for Fate Therapeutics has decreased to $22.40, down from $59.15, following analyst downgrades and target cuts.
Several analysts have lowered their price targets for Fate Therapeutics, with some targets decreasing by as much as $63, citing concerns over the company's pipeline and deal termination.

Announcements· Nov 18

Fate Therapeutics' FT522 showed efficacy in a Phase 2 B-cell lymphoma trial, with favorable safety profile, complete responses, and persistence of FT522 live cells.
The company presented 6-month follow-up data on the first patient treated in a Phase 1 autoimmunity study with FT819, an off-the-shelf, 1XX CAR T-cell product candidate, with fludarabine-free conditioning.
Fate Therapeutics highlighted its FT522 off-the-shelf, ADR-armed CAR NK cell product candidate at the 2024 ACR Convergence, showcasing its novel technology for effective treatment of patients without intense conditioning chemotherapy.

Generated by AI

Community

Of the messages about FATE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	82.76%	90.91%	65.43%
Newcomers	0%	17.24%	9.09%	34.57%

Regulars· May 4

STIFEL remains cautious on the potential of FT819 and FT576 to differentiate themselves from existing CAR-T therapies, citing a high clinical bar and competition from established treatments.
Cantor Fitzgerald has trimmed their target price for Fate Therapeutics to $5.00, citing concerns about the company's ability to meet the high expectations set by its clinical trials.
Fate Therapeutics has reported strong earnings results for Q1 2023, beating expectations by $0.36 EPS, but its shares have still declined by 9.3% due to concerns about the company's clinical trials and competitiveness.

Newcomers· Nov 18

The focus on Fate Therapeutics' FT819 product candidate is on its potential to provide a complete game-changer for off-the-shelf CAR T-cell therapy, with promising results in a Phase 1 Autoimmunity study for lupus nephritis.
The company's cash reserves and market capitalization are notable, with $330M in cash and a market cap of $300M, making it an attractive investment opportunity.
Fate Therapeutics' FT522 product candidate has demonstrated efficacy in a Phase 1 B-Cell Lymphoma trial, with promising initial data presented at the American College of Rheumatology Convergence.

Generated by AI

Fate Therapeutics

Social

Jul 1

Bullish· May 5

Bearish· Jan 9

Analysts· Jan 6

Announcements· Nov 18

Regulars· May 4

Newcomers· Nov 18

Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial

Fate Therapeutics receives $15m CIRM grant for lupus trial

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances

Fate Therapeutics presents FT819 lupus trial data at conference

Also Discussed

Fate Therapeutics Inc.

Company Information

Location

Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial

Fate Therapeutics receives $15m CIRM grant for lupus trial

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances

Fate Therapeutics presents FT819 lupus trial data at conference

Also Discussed

Social

Jul 1

Bullish· May 5

Bearish· Jan 9

Analysts· Jan 6

Announcements· Nov 18

Regulars· May 4

Newcomers· Nov 18